Regulation, Digitization Mulled As Swiss Medtechs Look To An ‘EU+’ Vision For The Future
Swiss Parliament addresses proposal to allow US FDA-approved products onto the market
Executive Summary
With Switzerland now operating as a third country to the EU, Swiss-based medtech manufacturers are keen to maximize their inherent advantages and build a basis for future growth.
You may also be interested in...
No MRA Means Switzerland’s Seamless IVDs Trade With The EU Is At An End
The EU’s full implementation of the In Vitro Diagnostic Regulation on 26 May has put the Swiss IVD industry on a "third country" footing with the EU, as happened in 2021 for medical devices. The two parties’ mutual recognition agreement for all medtech products has ceased to apply. A renewed MRA is not likely for several years.
View From German Industry: MDR At The Turning Point
Spectaris’ Marcus Kuhlmann describes Medica as a valued hub to meet member companies and host ecosystem and trade updates for the wider medtech industry. The German industry association’s medtech leader spoke to Medtech Insight during the 2022 event about the top concerns for manufacturers.
On-Prescription Apps Are Just One Vital Part Of Germany’s Digital Strategy
Are too few digital health care apps approved for reimbursement in Germany? That’s not the point, says the health care ministry, urging a look at the bigger strategic picture.